FDAapproval65% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (nmus rehab) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Not specified
- Sub-indication
- Nmus Rehab
Related signal: AstraZeneca Reports Strong Q1 2026 Revenue Growth and Positive NME Readouts